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Transforming growth factor-b1 (TGF-b1) regulates a wide variety of cellular responses, such as pro-
liferation, differentiation, migration and apoptosis. Here we report that death effector domain-con-
taining DNA-binding protein (DEDD) physically interacts with Smad3. The inhibition of Smad3 by
DEDD resulted in a reduction in TGF-b1/Smad3-mediated transcription. DEDD inhibited the func-
tions of Smad3 by preventing Smad3 phosphorylation, which led to the reduced expression of
TGF-b1/Smad3-targeted genes. TGF-b1 inhibited DEDD expression, and DEDD inhibited TGF-b1-med-
iated invasion. Therefore, our ﬁndings suggest that through its interaction with Smad3, DEDD is a
novel negative regulator of the TGF-b1 signaling pathway.
Structured summary:
MINT-7895480: DEDD (uniprotkb:O75618) physically interacts (MI:0915) with Smad3 (uni-
protkb:P84022) by anti bait co-immunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The transforming growth factor-b (TGF-b) family members,
which include the TGF-bs, activins, nodals and bone morphoge-
netic proteins, are secreted cytokines that regulate a broad array
of cellular responses including proliferation, differentiation, migra-
tion and apoptosis. The TGF-b1 signaling pathway is important in
metazoan biology, and its dysregulation can often result in tumor
development [1]. The TGF-b1 signaling pathway has been well
described [1,2]. Although TGF-b1/Smad-mediated signaling is con-
ceptually simple, the number of Smad-interacting proteins pro-
vides a high degree of signaling speciﬁcity and versatility [2].
Apoptotic signaling is regulated and mediated by specialized
proteins that often possess protein-protein interaction domains.
One of these domains is the death effector domain (DED), which
is predominantly found in components of the death receptor-
induced signaling complex that forms at death receptor family
members following their ligation. DED-containing proteins include
Fas-associated death domain protein (FADD), caspase-8 and death
effector domain-containing DNA-binding protein (DEDD) [3].
DEDD plays an important role in CD95-mediated apoptosis by acti-chemical Societies. Published by E
.vating caspase-3 or caspase-6 as a scaffold protein [4–6]. A recent
study found that DEDD can suppress the activity of the Cdk1/cyclin
B1 complex and maintain S6K1 activity, suggesting that DEDD par-
ticipates in regulation of the cell cycle and inhibits cell mitosis
[7,8]. However, it is unclear whether DEDD, through interactions
with key signaling proteins, is involved in other signaling path-
ways. Additionally, the pathophysiological functions of DEDD have
not been fully elucidated.
Using a yeast two-hybrid screen designed to identify Smad3-
interacting proteins, we have identiﬁed an interaction between
Smad3 and DEDD. We investigated the mechanism and functional
signiﬁcance of this interaction and found that DEDD inhibits the
function of Smad3 and suppresses TGF-b-mediated invasion. DEDD
itself also blocks cell invasion, suggesting that DEDD functions as a
tumor suppressor. To the best of our knowledge, this is the ﬁrst re-
port demonstrating that Smad3 interacts with DED-containing
proteins.2. Materials and methods
2.1. Cell culture and transfection
HEK 293T, HepG2 and HeLa cells were obtained from American
Type Culture Collection (ATCC) and were grown in Dulbecco’slsevier B.V. All rights reserved.
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serum (FBS). HEK 293T, HepG2 and HeLa cells were transfected
using Lipofectamine (Invitrogen) according to manufacturer’s
instructions.
2.2. Antibodies and reagents
The following antibodies were used: anti-HA-tag (F-7, sc-7392),
anti-Smad2/3 (FL-425, sc-8332), anti-Smad2/3 (N-19, sc-6032),
anti-DEDD (C-18, sc-27051), anti-p21 (F-5, sc-6246) and anti-b-Ac-
tin (C4, sc-47778) (Santa Cruz); anti-phospho-Smad3 (Ser423/425,
#9520) (Cell Signaling Technology); anti-Flag M2 (F-3165) (Sig-
ma); anti-Myc-tag (562-5) (MBL International); and anti-GAPDH
(KC-5G4) (KangChen Biotech). Recombinant human TGF-b1 was
purchased from Peprotech.
2.3. Plasmids
The expression vector encoding Flag-DEDD was a gift from Dr.
Marcus E. Peter (University of Chicago, USA). The vectors encoding
Flag-N-DEDD and Flag-C-DEDD were gifts from Dr. Toru Miyazaki
(University of Tokyo, Japan). The HA-FADD and Flag-caspase-8
expression vectors were gifts from Dr. Sug Hyung Lee (The Catholic
University of Korea, South Korea). The Flag-Smad7 expression vec-
tor was a gift from Dr. Carl-Henrik Heldin (Uppsala University,
Sweden). The SBE4-luc reporter plasmid was a gift from Dr. Bert
Vogelstein (Johns Hopkins University, USA), and p3TP-luc was a
gift from Dr. Joan Massagué (Memorial Sloan-Kettering Cancer
Center, USA). pcDNA3.1-Myc-Smad2, -Smad3, -Smad4, pcDNA3.1-
HA-DEDD, -GSK3b were generated by PCR and conﬁrmed by
sequencing.
2.4. Yeast two-hybrid screening
The yeast two-hybrid screen was performed according to Clon-
tech’s GAL4-based system. The full length Smad3 was ligated into
the pGBKT7 vector to create the pBD-Smad3 plasmid. The con-
struct was used to screen a human embryonic kidney library. The
transformants were selected on yeast media lacking leucine and
tryptophan and then transferred to quadruple dropout media also
lacking adenine and histidine. Colonies that were viable on qua-
druple selection media were subjected to a b-galactosidase assay.
False positives were eliminated by autoactivation test and co-
transformation. The remaining positive clones were then shuttled
into Escherichia coli DH5a cells, rescued and sequenced.
2.5. Co-immunoprecipitation and immunoblot analyses
HEK 293T and HepG2 cells were grown in 10 cm dishes and
transfected with the appropriate plasmids. They were washed once
with ice-cold PBS and lysed in ice-cold lysis buffer. After centrifu-
gation, the supernatants were collected, and the protein concentra-
tion was measured using the Bio-Rad Protein Assay Kit. An equal
amount of protein was used for immunoprecipitation, and the pre-
cipitated proteins were subjected to SDS–PAGE in 8%, 10% or 12%
polyacrylamide gels and blotted onto polyvinylidene diﬂuoride
membranes, as previously described [9].
2.6. GST pull-down assays
The GST-Smad3 fusion protein was expressed in E. coli and puri-
ﬁed using glutathione–sepharose 4B beads. Equal amounts of GST
or GST-fusion proteins bound to glutathione–sepharose beads
were incubated overnight with cell lysates from HEK 293T cells
overexpressing HA-DEDD. The bound complexes were eluted and
analyzed using an immunoblot.2.7. Luciferase reporter assays
HEK 293T and HepG2 cells were transiently co-transfected with
the empty vector; the Myc-Smad3 expression vector; the indicated
DEDD construct or HA-FADD; and the SBE4-luc, p3TP-Luc reporter
construct. Luciferase activity was measured using a Dual Luciferase
Assay System (Promega).
2.8. siRNA
SMART pool siRNA duplexes speciﬁc for DEDD and a non-
targeting siRNA (siControl) were purchased from Dharmacon.
HepG2 cells were transfected with the DEDD-speciﬁc or control
siRNA using Lipofectamine (Invitrogen) according to manu-
facturer’s instructions. The cells were cultured in serum-free
medium for the indicated time, and TGF-b1 was added 24 h after
transfection.
2.9. RT-PCR
Total RNA was extracted using Trizol (Invitrogen). Reverse tran-
scription of the total cellular RNA was carried out using oligo-dT
primers and M-MLV Reverse Transcriptase (Promega) according
to manufacturer’s instruction.
2.10. Cell invasion assay
In preliminary study, we found that transfection of DEDD did
not affect cell proliferation in HeLa cells which were used for the
invasion assay. The cell density was adjusted to 2.5  105/ml,
and 200 ll of this suspension was added to the top chamber of a
24-well transwell plate (Millipore; 8-lm pore size) coated with
Matrigel. The medium in the upper chamber was serum-free
DMEM, and the medium in the lower chamber was supplemented
with 10% fetal bovine serum. After incubation for 20 h at 37 C, the
cells that invaded through the ﬁlter were stained and counted in
six random ﬁelds of view at 200 magniﬁcation. The data are ex-
pressed as the average number of cells per ﬁeld of view.
2.11. Statistical analysis
The data are expressed as the mean ± S.E. Statistical analyses
were performed using a paired Student’s t-test. A p-value less than
0.05 was considered signiﬁcant.3. Results
3.1. Identiﬁcation of DEDD as a Smad3-interacting protein
A yeast two-hybrid screening system was used to identify pro-
teins that interact with Smad3 and 34 positive clones were identi-
ﬁed and sequenced. Of these clones, one contained a cDNA
encoding DEDD. To validate the yeast two-hybrid screen results,
pAD-DEDD and pBD-Smad3 were co-transfected into yeast
AH109 cells, grown in high-stringency medium (SD-Ade/-His/-
Leu/-Trp) and tested for b-galactosidase activity. As shown in
Fig. 1A, yeast cells expressing pAD-DEDD and pBD-Smad3 grew
in high-stringency medium and showed positive galactosidase
activity. To examine the in vivo interaction between DEDD and
Smad3, HEK 293T cells were ﬁrst co-transfected with an HA-tagged
DEDD expression vector and various Myc-tagged Smad expression
vectors. DEDD could be co-precipitated with Smad3, slightly co-
precipitated with Smad4 and inhibitory Smad7 proteins, but not
with the highly homologous Smad2 (Fig. 1B). To test whether the
DED of DEDD was needed for the binding of DEDD to Smad3, DEDD
Fig. 1. DEDD interacts with Smad3. (A) Identiﬁcation of DEDD as a partner of Smad3 by a yeast two-hybrid screen. pCL1 (yeast strain constitutively expressing b-
galactosidase) and p53/large T-antigen (yeast strain with interacting p53 and large T-antigen) were used as positive controls, lamin C large T-antigen (lamin C and non-
interacting large T-antigen containing yeast strain) was used as negative control. ++, +,  indicate strong, medium, and no interaction, respectively. (B) Co-
immunoprecipitation of DEDD and Smad3. Myc-tagged Smads were expressed with HA-DEDD in HEK 293T cells and isolated by immunoprecipitation using an anti-Myc
antibody. Smad-bound DEDD was detected using an immunoblot with an anti-HA antibody. The immunoprecipitated proteins were blotted with an anti-Myc antibody to
control for Smad expression. Whole cell lysates were blotted with anti-HA and anti-Myc antibodies to control for HA-DEDD and Myc-Smad expression, respectively. (C) The
DED of DEDD is involved in the interaction with Smad3. (Upper) Schematic illustration shows the structure of F-DEDD, N-DEDD and C-DEDD. (Lower) Different domains of
DEDD were coexpressed with Smad3 in HEK 293T cells and analyzed as indicated. (D) Co-immunoprecipitation of endogenous DEDD with Smad3 in HepG2 cells. NS indicates
a non-speciﬁc band. (E) Binding assay for HA-DEDD and GST-Smad3. Cell lysates from HEK 293T overexpressing HA-tagged DEDD were incubated with equal amounts of GST
and GST-Smad3 and analyzed by Western blot using anti-HA antibody (top panels). The presence of the GST-fusion proteins was conﬁrmed by staining gels with Coomassie
Blue. HA-tagged GSK3b protein was used as a positive control.
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minal region without the DED (C-DEDD) were generated as previ-
ously described [7]. N-DEDD, but not C-DEDD, bound Smad3,
clearly indicating that the DED was involved in the association of
DEDD with Smad3 (Fig. 1C). We then determined whether
endogenous DEDD and Smad3 also interact. As shown in Fig. 1D,
endogenous DEDD associated with Smad3 in HepG2 cells. To
further determine the interaction between DEDD and Smad3, we
performed GST pull-down assays. GST and GST-Smad3 fusion
proteins were used to test their interaction with HA-tagged
DEDD. GSK3b had been reported to interact with Smad3 [10], so
we used HA-tagged GSK3b in the pull-down assay as a positive
control. As shown in Fig. 1E, DEDD bound to GST-Smad3 but not
GST alone.3.2. DEDD inhibits TGF-b1/Smad3 transcriptional activity
To explore the functional role of the DEDD-Smad3 interaction in
the regulation of the TGF-b1/Smad3 signaling pathway, we tested
the role of DEDD in regulating Smad3-mediated transcription. As
reported previously [11], the overexpression of Smad3 activated
the transcription of SBE4-Luc, a TGF-b1-responsive reporter gene
that contains the Smad-binding element (SBE), even in the absence
of TGF-b1 stimulation. The expression of DEDD inhibited this acti-
vation in HEK 293T and HepG2 cells. N-DEDD, but neither C-DEDD
nor FADD (another DED-containing protein), decreased Smad3-
mediated transcription, suggesting that the DED of DEDD was re-
quired for repression of the Smad3-induced transcriptional re-
sponse (Fig. 2A and B). We also co-transfected the DEDD
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construct into HEK 293T or HepG2 cells; the expression of DEDD
resulted in a decrease in TGF-b1-induced transactivation (Fig. 2C
and D).
3.3. DEDD inhibits Smad3-mediated function
We then examined whether the binding of DEDD to Smad3 af-
fects the phosphorylation of Smad3 in response to TGF-b1. TGF-b1-
induced phosphorylation of Smad3 was reduced in HepG2 cells
overexpressing DEDD. Furthermore, the level of phosphorylationFig. 2. DEDD attenuates TGF-b1/Smad3-dependent transcription. (A and B) DEDD inhibit
of Smad3-mediated transcription. HEK 293T (A) and HepG2 (B) cells were transfected
empty expression vector, the Myc-Smad3 expression vector alone, the DEDD expression v
measured 48 h after transfection. The data are presented as the mean ± S.D. of three exper
transcription. HEK 293T (C) and HepG2 (D) cells were transfected with the 3TP-luciferase
or the HA-DEDD expression vector. Luciferase activity was measured 24 h after incub
experiments in triplicate. **P < 0.01.
Fig. 3. DEDD attenuates the activation of TGF-b1/Smad3 signaling. (A) DEDD attenuates
HepG2 cells were co-transfected with either 5 lg/well of empty vector or DEDD expressi
1 h. GAPDH was used as a loading control. (B) siRNA-mediated silencing of DEDD enhance
a non-speciﬁc band. Data are representative immunoblots of three experiments.of Smad3 was enhanced upon siRNA-mediated knockdown of
DEDD in the presence of TGF-b1 (Fig. 3). To investigate the effect
of DEDD on endogenous protein expression induced by TGF-b1,
we treated HepG2 cells with TGF-b1 for 1 h and tested the expres-
sion level of p21, an inhibitor of cell cycle progression that is
upregulated following TGF-b1 stimulation, using an immunoblot.
As shown in Fig. 3, TGF-b1 induced the expression of p21, and
overexpression of DEDD inhibited the induction of p21 by TGF-
b1. However, decreasing the endogenous DEDD level using
DEDD-speciﬁc siRNAs resulted in potentiated TGF-b1-induced
upregulation of p21.s Smad3-activated transcription and the DED of DEDD is required for the inhibition
with SBE4-luciferase (SBE4-luc) and pRL-TK reporter constructs together with the
ectors alone or the expression vectors together, as indicated. Luciferase activity was
iments in triplicate. **P < 0.01; ***P < 0.001. (C and D) DEDD inhibits TGF-b1-induced
(3TP-luc) and pRL-TK reporter constructs together with the empty expression vector
ation of cells with or without 5 ng/ml of TGF-b1. Data are mean ± S.D. of three
TGF-b1-induced phosphorylation of Smad3 and the expression of endogenous p21.
on vector in a 6-well plate. Cells were treated with or without TGF-b1 (10 ng/ml) for
s TGF-b1-induced Smad3 phosphorylation and p21 protein expression. NS indicates
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To investigate whether TGF-b1 regulates DEDD function, we
examined the effect of TGF-b1 on the expression level of DEDD.
As detected using both RT-PCR and immunoblot, the level of both
DEDD mRNA and protein, started to decrease 15 min after TGF-
b1 treatment; however, the protein and mRNA levels gradually
recovered afterwards (Fig. 4A and B).
3.5. DEDD inhibits TGF-b1-mediated invasion
To determine whether the DEDD-Smad3 interaction regulated
downstream biological responses, we examined the effect of TGF-
b1 on the invasiveness of HeLa cells using a Matrigel invasion as-Fig. 4. TGF-b1 attenuates DEDD expression in HepG2 cells. (A) The mRNA expression of D
with or without TGF-b1 for the indicated time. (B) HepG2 cells were stimulated with or w
used for immunoblot analysis with an antibody against DEDD (upper panels) or GAPDH
Fig. 5. DEDD inhibits TGF-b1-mediated invasion. (A) DEDD inhibits TGF-b1-mediated inv
to the in vitro invasion assay described in Section 2. *P < 0.05. (B) siRNA-mediated silensay. In cells transfected with empty vector or control siRNA, TGF-
b1 treatment caused an increase in the number of migrating cells
compared with untreated control cells. In contrast, the overexpres-
sion of DEDD inhibited TGF-b1-induced cell invasion (Fig. 5A). Con-
sistent with this observation, the inhibition of DEDD expression
using DEDD-speciﬁc siRNAs markedly enhanced the invasion of
HeLa cells regardless of treatment with TGF-b1 (Fig. 5B).
4. Discussion
Speciﬁc and diverse TGF-b1 signaling depends on Smad proteins
as a node for the integration of TGF-b1 signaling with other signal-
ing pathways [2]. Many recent studies have focused on the identi-
ﬁcation of proteins that regulate TGF-b1 signaling throughEDD was assessed using RT-PCR on RNA samples isolated from HepG2 cells treated
ithout TGF-b1 (10 ng/ml) for the indicated time. The obtained total cell lysates were
(lower panels).
asion of HeLa cells. Cells that migrated through Matrigel were quantiﬁed according
cing of DEDD enhances TGF-b1-mediated invasion of HeLa cells. **P < 0.01.
Fig. 6. A model for the role of DEDD in the regulation of TGF-b1/Smad3 signaling. In quiescent cells, DEDD binds directly to Smad3, interfering with and/or masking Smad3
from phosphorylation. Upon TGF-b1 activation, DEDD disassociates from Smad3, exposing the phosphorylation site of Smad3. Phosphorylated Smad3 is then translocated into
the nucleus where it activates transcription. The free DEDD in the cytoplasm is decreased through a currently unknown mechanism.
J.-F. Xue et al. / FEBS Letters 584 (2010) 3028–3034 3033interactions with Smad proteins [12]. Indeed, by co-immunopre-
cipitation assay we found that DEDD interacts with Smad3 and
that this association is mediated by the DED of DEDD, consistent
with the description of the DED as a protein–protein interaction
domain [4,5]. Furthermore, our data also suggest that N-DEDD,
but not C-DEDD, inhibits TGF-b1/Smad3-induced transcription.
These results further conﬁrm that DEDD performs its function pri-
marily through the DED [7]. The fact that other DED-containing
proteins, such as FADD and caspase-8, do not interact with Smad3
(data not shown) suggests that the interaction between DEDD and
Smad3 is speciﬁc.
Our study demonstrates that DEDD inhibits the function of
Smad3 by inhibiting Smad3 phosphorylation. Based on the results
from this study and others [4], we propose a model for the role of
DEDD in the regulation of TGF-b1/Smad3 signaling (Fig. 6). We pro-
pose that in a quiescent cell, DEDD acts as a scaffolding molecule in
the cytoplasm which physically binds to Smad3, sequestering
Smad3 in the cytosol and/or blocking its activation by binding di-
rectly to and masking the C-terminal Ser phosphorylation sites of
Smad3. After activation of TGF-b1 receptors, TGF-b1 may down-
regulate the expression of DEDD or decrease DEDD stability by a
currently unknown mechanism, thus reducing the formation of
the DEDD–Smad3 complex. As a result, phosphorylated Smad3 is
able to translocate to the nucleus where it regulates the transcrip-
tion of target genes. Indeed, our data suggests that DEDD interferes
with Smad3 phosphorylation, as well as Akt [11]. However, more
work is required to understand how DEDD is regulated by TGF-b1.
TGF-b1 regulates a wide range of cellular responses. TGF-b1 can
enhance the apoptotic, migratory and invasive properties of cancer
cells [13,14]. In this report, we found that DEDD inhibited TGF-b1-
mediated invasion, which is consistent with previous reports dem-
onstrating that many proteins that interact with Smad3 were capa-
ble of inhibiting the biological functions mediated by TGF-b1 [10].
Unexpectedly, our results also suggest that DEDD does not modu-
late TGF-b1-induced epithelial-to-mesenchymal transition (EMT;
data not shown). Since TGF-b1 promotes the EMT through a com-
bination of Smad-dependent transcriptional events and Smad-
independent effects on cell-junction complexes [13], it is possible
that the factors responsible for the TGF-b1-induced EMT are not af-fected by the interaction between DEDD and Smad3. With a better
understanding of the role of TGF-b1 in cancer, targeting of TGF-b1
for cancer treatment may become feasible [1]. In recent years, a
number of studies have demonstrated the therapeutic potential
of various TGF-b1 antagonists as anti-metastatic drugs [15]. As a
result, the modulation of DEDD expression may prove to be a use-
ful method of speciﬁcally regulating the proinvasive and meta-
static responses of TGF-b1.
In summary, our study indicates that DEDD interacts physically
with the transcription factor Smad3 and inhibits its functions,
thereby attenuating TGF-b1-mediated cell invasion. Furthermore,
DEDD itself blocks tumor cell invasiveness. These ﬁndings suggest
that DEDD may be a candidate target for cancer therapy, but more
work will be required to conﬁrm this idea.Acknowledgments
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